Mar Tintore

List of Publications by Year
in descending order

165 papers	14,967 citations	34016 52 h-index	19690 117 g-index
170 all docs	170 docs citations	170 times ranked	10897 citing authors

#	Article	IF	Citations
1	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	4.9	4,605
2	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurology, The, 2016, 15, 292-303.	4.9	679
3	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nature Reviews Neurology, 2015, 11, 597-606.	4.9	422
4	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain, 2015, 138, 1863-1874.	3.7	403
5	Sex and gender issues in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2013, 6, 237-248.	1.5	368
6	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process. Nature Reviews Neurology, 2015, 11, 471-482.	4.9	354
7	2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurology, The, 2021, 20, 653-670.	4.9	302
8	Defining the response to interferon–β in relapsing–remitting multiple sclerosis patients. Annals of Neurology, 2006, 59, 344-352.	2.8	295
9	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurology, The, 2007, 6, 677-686.	4.9	292
10	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	4.9	261
11	Radiologically Isolated Syndrome: 5-Year Risk for an Initial Clinical Event. PLoS ONE, 2014, 9, e90509.	1.1	254
12	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain, 2010, 133, 1082-1093.	3.7	240
13	Treatment of multiple sclerosis — success from bench to bedside. Nature Reviews Neurology, 2019, 15, 53-58.	4.9	239
14	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	0.9	228
15	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. Lancet Neurology, The, 2020, 19, 234-246.	4.9	207
16	Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 306-309.	1.4	184
17	Elevated Epstein–Barr virus–encoded nuclear antigen–1 immune responses predict conversion to multiple sclerosis. Annals of Neurology, 2010, 67, 159-169.	2.8	181
18	Treatment decisions in multiple sclerosis — insights from real-world observational studies. Nature Reviews Neurology, 2017, 13, 105-118.	4.9	154

#	ARTICLE	IF	CITATIONS
19	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	4.9	150
20	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. Brain, 2015, 138, 918-931.	3.7	147
21	Primary <scp>P</scp>rogressive <scp>M</scp>ultiple <scp>S</scp>clerosis <scp>E</scp>volving <scp>F</scp>rom <scp>R</scp>adiologically <scp>I</scp>solated <scp>S</scp>yndrome. Annals of Neurology, 2016, 79, 288-294.	2.8	130
22	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibodyâ€"Associated Disease. Annals of Neurology, 2021, 89, 30-41.	2.8	123
23	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain, 2018, 141, 1085-1093.	3.7	115
24	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon Î²: Implications for clinical trials. Annals of Neurology, 2002, 52, 400-406.	2.8	114
25	A Single, Early Magnetic Resonance Imaging Study in the Diagnosis of Multiple Sclerosis. Archives of Neurology, 2009, 66, 587-92.	4.9	114
26	Encephalopathy associated to autoimmune thyroid disease: a more appropriate term for an underestimated condition?. Journal of the Neurological Sciences, 2000, 176, 65-69.	0.3	113
27	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurology, The, 2006, 5, 221-227.	4.9	112
28	COVIDâ€19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. European Journal of Neurology, 2021, 28, 3384-3395.	1.7	111
29	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197.	4.9	110
30	Is optic neuritis more benign than other first attacks in multiple sclerosis?. Annals of Neurology, 2005, 57, 210-215.	2.8	108
31	Assessing response to interferon-Î² in a multicenter dataset of patients with MS. Neurology, 2016, 87, 134-140.	1.5	98
32	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain, 2018, 141, 1075-1084.	3.7	98
33	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurology, The, 2018, 17, 133-142.	4.9	98
34	The potential of serum neurofilament as biomarker for multiple sclerosis. Brain, 2021, 144, 2954-2963.	3.7	98
35	Radiologically Isolated Syndrome: <scp>10â€Year</scp> Risk Estimate of a Clinical Event. Annals of Neurology, 2020, 88, 407-417.	2.8	95
36	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. Multiple Sclerosis Journal, 2013, 19, 1175-1181.	1.4	93

#	Article	IF	Citations
37	Unraveling treatment response in multiple sclerosis. Neurology, 2019, 92, 180-192.	1.5	88
38	Neurofilament light chain level is a weak risk factor for the development of MS. Neurology, 2016, 87, 1076-1084.	1.5	85
39	Will Rogers phenomenon in multiple sclerosis. Annals of Neurology, 2008, 64, 428-433.	2.8	80
40	Therapeutic Decisions in Multiple Sclerosis. JAMA Neurology, 2013, 70, 1315-24.	4.5	80
41	Rationale for early intervention with immunomodulatory treatments. Journal of Neurology, 2008, 255, 37-43.	1.8	79
42	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. Multiple Sclerosis Journal, 2018, 24, 301-312.	1.4	79
43	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β. Journal of Neuroimmunology, 2002, 130, 194-201.	1.1	78
44	Radiologically isolated syndrome or subclinical multiple sclerosis: MAGNIMS consensus recommendations. Multiple Sclerosis Journal, 2018, 24, 214-221.	1.4	77
45	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Multiple Sclerosis Journal, 2018, 24, 1843-1851.	1.4	77
46	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 1001-1008.	1.2	68
47	Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. Multiple Sclerosis Journal, 2006, 12, 487-494.	1.4	67
48	A three-year, multi-parametric MRI study in patients at presentation with CIS. Journal of Neurology, 2008, 255, 683-691.	1.8	65
49	The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Preference and Adherence, 2017, Volume 11, 33-45.	0.8	65
50	Multiple sclerosis management during the COVID-19 pandemic. Multiple Sclerosis Journal, 2020, 26, 1163-1171.	1.4	63
51	Disability progression markers over 6–12 years in interferon-β-treated multiple sclerosis patients. Multiple Sclerosis Journal, 2018, 24, 322-330.	1.4	60
52	Interferon beta in relapsing–remitting multiple sclerosis. Journal of Neurology, 2005, 252, 795-800.	1.8	59
53	Sex effects across the lifespan in women with multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093616.	1.5	58
54	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain, 2020, 143, 2637-2652.	3.7	56

#	Article	IF	Citations
55	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology, 2013, 80, 234-241.	1.5	53
56	N-Acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. Journal of Neurology, 2014, 261, 2338-2343.	1.8	52
57	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Frontiers in Neurology, 2020, 11, 632.	1.1	52
58	Antimyelin Antibodies with No Progression to Multiple Sclerosis. New England Journal of Medicine, 2007, 356, 426-428.	13.9	50
59	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2019, 92, e1507-e1516.	1.5	49
60	Lipid–specific immunoglobulin <scp>M</scp> bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Annals of Neurology, 2015, 77, 447-457.	2.8	48
61	The role of the cerebellum in multiple sclerosis—150 years after Charcot. Neuroscience and Biobehavioral Reviews, 2018, 89, 85-98.	2.9	48
62	Interferon Beta-1b for the Treatment of Primary Progressive Multiple Sclerosis. Archives of Neurology, 2011, 68, 1421.	4.9	44
63	Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. Annals of Neurology, 2001, 49, 408-411.	2.8	42
64	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. Neurology, 2016, 87, 1368-1374.	1.5	42
65	SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis. NeuroImage: Clinical, 2019, 24, 102011.	1.4	42
66	Radiologically isolated syndrome in children. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e395.	3.1	41
67	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. Multiple Sclerosis Journal, 2020, 26, 1658-1669.	1.4	41
68	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	1.4	39
69	Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. Journal of Neurology, 2022, 269, 1670-1677.	1.8	39
70	Altered maturation of circulating dendritic cells in primary progressive MS patients. Journal of Neuroimmunology, 2006, 175, 183-191.	1.1	37
71	Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients. Multiple Sclerosis Journal, 2014, 20, 1602-1608.	1.4	36
72	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. Neurology, 2021, 97, e1641-e1652.	1.5	35

#	Article	IF	Citations
73	Early onset multiple sclerosis: The role of gender. Journal of the Neurological Sciences, 2009, 286, 31-34.	0.3	33
74	Specificity of Barkhof Criteria in Predicting Conversion to Multiple Sclerosis When Applied to Clinically Isolated Brainstem Syndromes. Archives of Neurology, 2004, 61, 222.	4.9	32
75	Optic Nerve Topography in Multiple Sclerosis Diagnosis. Neurology, 2021, 96, e482-e490.	1.5	32
76	Early predictors of multiple sclerosis after a typical clinically isolated syndrome. Multiple Sclerosis Journal, 2014, 20, 1721-1726.	1.4	31
77	Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey. Multiple Sclerosis Journal, 2022, 28, 132-138.	1.4	31
78	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. Neurology, 2022, 98, .	1.5	31
79	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. Multiple Sclerosis Journal, 2004, 10, 413-416.	1.4	30
80	Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields. American Journal of Neuroradiology, 2016, 37, 1816-1823.	1.2	30
81	<i>TNFRSF1A</i> polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. Neurology, 2013, 80, 2010-2016.	1.5	28
82	Validation of semaphorin 7A and ala-Î²-his-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. Journal of Neuroinflammation, 2014, 11, 181.	3.1	28
83	Predictive value of early brain atrophy on response in patients treated with interferon Î². Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e132.	3.1	28
84	Lesion topographies in multiple sclerosis diagnosis. Neurology, 2017, 89, 2351-2356.	1.5	27
85	Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2020, 41, 461-463.	1.2	27
86	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. Journal of Neuroinflammation, 2015, 12, 48.	3.1	26
87	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. Multiple Sclerosis Journal, 2014, 20, 1471-1477.	1.4	25
88	Keeping standards of multiple sclerosis care through the COVID-19 pandemic. Multiple Sclerosis Journal, 2020, 26, 1153-1156.	1.4	24
89	Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment. PLoS ONE, 2013, 8, e82796.	1.1	23
90	Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731983666.	0.5	23

#	ARTICLE	IF	CITATIONS
91	Brain Volume Loss During the First Year of Interferon‑Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. Journal of Neuroimaging, 2016, 26, 532-538.	1.0	21
92	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. Multiple Sclerosis Journal, 2017, 23, 556-566.	1.4	21
93	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	1.4	21
94	Head-to-head drug comparisons in multiple sclerosis. Neurology, 2019, 93, 793-809.	1.5	20
95	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. Multiple Sclerosis Journal, 2021, 27, 913-921.	1.4	20
96	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. Multiple Sclerosis Journal, 2012, 18, 1193-1196.	1.4	19
97	Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arquivos De Neuro-Psiquiatria, 2013, 71, 275-279.	0.3	19
98	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Multiple Sclerosis Journal, 2018, 24, 1485-1498.	1.4	19
99	Unconventional therapy in multiple sclerosis. Multiple Sclerosis Journal, 2003, 9, 320-322.	1.4	18
100	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	0.9	18
101	FXTAS in Spanish Patients with Ataxia: Support for Female FMR1 Premutation Screening. Molecular Neurobiology, 2007, 35, 324-328.	1.9	17
102	Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. American Journal of Neuroradiology, 2018, 39, 399-404.	1.2	17
103	Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab. Multiple Sclerosis Journal, 2018, 24, 358-360.	1.4	17
104	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, e1143.	3.1	17
105	Decreased cholecystokinin levels in cerebrospinal fluid of patients with adult chronic hydrocephalus syndrome. Biological Psychiatry, 1997, 41, 804-809.	0.7	16
106	New options for early treatment of multiple sclerosis. Journal of the Neurological Sciences, 2009, 277, S9-S11.	0.3	16
107	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. European Journal of Neurology, 2022, 29, 1075-1081.	1.7	16
108	Scoring the 10‑year risk of ambulatory disability in multiple sclerosis: the RoAD score. European Journal of Neurology, 2021, 28, 2533-2542.	1.7	16

#	Article	IF	Citations
109	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	1.4	16
110	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. Neuroradiology, 2019, 61, 667-674.	1.1	15
111	Simultaneous CMV and <i>Listeria</i> infection following alemtuzumab treatment for multiple sclerosis. Neurology, 2019, 92, 296-298.	1.5	15
112	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Multiple Sclerosis Journal, 2022, 28, 1131-1137.	1.4	13
113	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations. NeuroImage: Clinical, 2022, 34, 102967.	1.4	13
114	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. Journal of Neuroimmunology, 2015, 288, 98-101.	1.1	12
115	Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2017, 38, 1486-1493.	1.2	12
116	Serial proton spectroscopy, magnetization transfer ratio andT2relaxation in pseudotumoral demyelinating lesions. NMR in Biomedicine, 2002, 15, 284-292.	1.6	11
117	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. Multiple Sclerosis Journal, 2022, 28, 1138-1145.	1.4	11
118	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. Multiple Sclerosis Journal, 2015, 21, 1802-1810.	1.4	10
119	CSF examination still has value in the diagnosis of MS â€" Commentary. Multiple Sclerosis Journal, 2016, 22, 997-998.	1.4	10
120	A validation study of manual atrophy measures in patients with MultipleÂSclerosis. Neuroradiology, 2020, 62, 955-964.	1.1	10
121	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. Multiple Sclerosis Journal, 2022, 28, 71-81.	1.4	10
122	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsingâ€"remitting multiple sclerosis patients. Journal of Neurology, 2022, 269, 452-459.	1.8	10
123	Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. Neurology, 2018, 91, 622-624.	1.5	9
124	Lesion location may predict disability in multiple sclerosis. Nature Reviews Neurology, 2010, 6, 648-649.	4.9	8
125	Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. Multiple Sclerosis Journal, 2018, 24, 1383-1385.	1.4	8
126	Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy. Multiple Sclerosis Journal, 2022, 28, 173-182.	1.4	8

#	ARTICLE	IF	CITATIONS
127	Women's Health in Multiple Sclerosis: A Scoping Review. Frontiers in Neurology, 2021, 12, 812147.	1.1	8
128	Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 732-740.	0.9	8
129	Dimethyl fumarate is coming of age. Nature Reviews Neurology, 2016, 12, 436-437.	4.9	7
130	Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria. Multiple Sclerosis Journal, 2019, 25, 1690-1691.	1.4	7
131	Prognostication and contemporary management of clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 391-397.	0.9	7
132	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 950-957.	1.4	7
133	New treatment measurements for treatment effects on relapses and progression. Journal of the Neurological Sciences, 2008, 274, 80-83.	0.3	6
134	Spinal cord MRI should always be performed in clinically isolated syndrome patients: No. Multiple Sclerosis Journal, 2014, 20, 1686-1687.	1.4	6
135	Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses. Multiple Sclerosis Journal, 2016, 22, 117-121.	1.4	6
136	The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS â€" No. Multiple Sclerosis Journal, 2018, 24, 123-125.	1.4	6
137	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. Multiple Sclerosis Journal, 2018, 24, 721-727.	1.4	6
138	B cell expression of the inhibitory FcÎ³ receptor is unchanged in early MS. Journal of Neuroimmunology, 2010, 223, 135-137.	1.1	5
139	MRI criteria distinguishing seropositive NMO spectrum disorder from MS. Neurology, 2013, 80, 1336-1336.	1.5	5
140	Serum Biomarker gMS-Classifier2: Predicting Conversion to Clinically Definite Multiple Sclerosis. PLoS ONE, 2013, 8, e59953.	1.1	5
141	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre. Journal of Neurology, 2022, 269, 1764-1772.	1.8	5
142	Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange. Journal of Neurology, 2003, 250, 243-244.	1.8	4
143	Interferon beta in secondary progressive multiple sclerosis. Journal of Neurology, 2007, 254, 849-853.	1.8	4
144	The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament levelâ€"NO. Multiple Sclerosis Journal, 2015, 21, 1240-1242.	1.4	4

#	ARTICLE	IF	CITATIONS
145	Multiple sclerosis risk perception and acceptance for Brazilian patients. Arquivos De Neuro-Psiquiatria, 2018, 76, 6-12.	0.3	4
146	Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Multiple Sclerosis and Related Disorders, 2021, 49, 102717.	0.9	4
147	Multiple sclerosis is associated with higher comorbidity and health care resource use: A populationâ€based, caseâ€"control study in a western Mediterranean region. European Journal of Neurology, 2021, 28, 4124-4134.	1.7	4
148	Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. Multiple Sclerosis Journal, 2022, 28, 1209-1218.	1.4	4
149	Novel triggers, treatment targets and brain atrophy measures. Nature Reviews Neurology, 2014, 10, 72-73.	4.9	3
150	Sustained reduction of MS disability. Neurology, 2016, 87, 1966-1967.	1.5	3
151	An asymptomatic new lesion on MRI is a relapse and should be treated accordingly â€" Commentary. Multiple Sclerosis Journal, 2019, 25, 1845-1847.	1.4	3
152	Diagnosis of multiple sclerosis: what is changing?. Expert Review of Neurotherapeutics, 2020, 20, 743-746.	1.4	3
153	The Multiple Sclerosis Data Alliance Catalogue. International Journal of MS Care, 2021, 23, 261-268.	0.4	3
154	Advances in the management of multiple sclerosis symptoms: pathophysiology and assessment of spasticity in multiple sclerosis. Neurodegenerative Disease Management, 2015, 5, 15-17.	1.2	2
155	Adding brain volume measures into response criteria in multiple sclerosis: the RÃo-4 score. Neuroradiology, 2021, 63, 1031-1041.	1.1	2
156	Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach. Neuroradiology, 2022, 64, 1383-1390.	1.1	2
157	Neurotoxicityâ€associated sinus bradycardia after chimeric antigen receptor Tâ€cell therapy. Hematological Oncology, 2022, , .	0.8	2
158	DMTs should be trialed in individuals with PPMS and SPMS with or without recent disease activity â€" Commentary. Multiple Sclerosis Journal, 2022, 28, 187-188.	1.4	2
159	Understanding the role of gender and hormones in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 518-519.	1.4	1
160	Symptom tracking: from clinically isolated syndrome to advanced multiple sclerosis. Neurodegenerative Disease Management, 2016, 6, 27-29.	1.2	1
161	Multiple sclerosis in the Middle East and North Africa region. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2020, 6, 205521731989554.	0.5	1
162	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. Neuroscience Informatics, 2022, 2, 100071.	2.8	1

#	Article	IF	Citations
163	Comment on: â€˜Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patientsâ€™. Multiple Sclerosis Journal, 2014, 20, 897-898.	1.4	0
164	The first volume of MSJ-ETC. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2016, 2, 205521731562604.	0.5	0
165	Author response: Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. Neurology, 2020, 94, 456-457.	1.5	0